| Literature DB >> 35407243 |
Danielle Mulder1, Cornelius Johannes Francois Taute1, Mari van Wyk1, Pieter J Pretorius1.
Abstract
Gold nanoparticles (GNPs) have shown great potential in diagnostic and therapeutic applications in diseases, such as cancer. Despite GNP versatility, there is conflicting data regarding the toxicity of their overall functionalization chemistry for improved biocompatibility. This study aimed to determine the possible genotoxic effects of functionalized GNPs in Human hepatocellular carcinoma (HepG2) cells. GNPs were synthesized and biofunctionalized with seven common molecules used for biomedical applications. These ligands were bovine serum albumin (BSA), poly(sodium 4-styrene sulfonate) (PSSNA), trisodium citrate (citrate), mercaptoundecanoic acid (MUA), glutathione (GSH), polyvinylpyrrolidone (PVP), and polyethylene glycol (PEG). Before in vitro genotoxicity assessment, inductively coupled plasma mass spectrometry was used to determine GNP cellular internalization quantitatively, followed by cell-based assays; WST-1 to find IC 30 and ApoPercentage for apoptotic induction time-points. The effect of the GNPs on cell growth in real-time was determined by using xCELLigence, followed by a comet assay for genotoxicity determination. The HepG2 cells experienced genotoxicity for all GNP ligands; however, they were able to initiate repair mechanisms and recover DNA damage, except for two functionalization chemistries.Entities:
Keywords: HepG2; biofunctionalization; comet assay; cytotoxicity; genotoxicity; gold nanoparticles
Year: 2022 PMID: 35407243 PMCID: PMC9000686 DOI: 10.3390/nano12071126
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Flow diagram showing the various methods used in this study.
Figure 2(a) High-resolution transmission electron microscopy micrograph of the citrate capped GNPs. (b) Percentage of GNP size distribution on 230 particles analyzed. (c) UV-Vis spectra of the functionalized GNP-ligands post sample clean-up.
Summary of the GNP-ligand characteristics.
| Ligand | Gel Electrophoresis: Particle Charge | DLS: Hydrodynamic Diameter (nm) |
|---|---|---|
| BSA | Negative | 23.32 |
| Citrate | Negative | 17.40 |
| GSH | Negative | 17.33 |
| MUA | Negative | 17.21 |
| PEG | Neutral | 18.86 |
| PSSNA | Negative | 17.26 |
| PVP | Negative | 18.96 |
Figure 3Cytotoxicity of the GNP-ligands at a range of concentrations on HepG2 cells (the ligand control contained ligand only in the same concentration as the highest concentration used, no GNP present). This data is based on an average of triplicate readings obtained for each concentration.
Cytotoxicity and cell entry of GNP-ligands.
| Ligand | * WST-1 | ICP-MS | ApoPercentage | ||||
|---|---|---|---|---|---|---|---|
| IC 30 (pM) | Cell % | Normalized IC30 (pM) | Fold Change in Cytotoxicity/Relative Cytotoxicity | PBS % | Media % | Apoptotic Time-Point | |
| BSA | 430 ± 2.96 | 2 | 9 | 47.8 ± 2.96 | 2 | 96 | Stepwise |
| Citrate | 860 ± 4.78 | 17 | 146 | 5.9 ± 4.78 | 3 | 80 | Stepwise |
| GSH | 220 ± 4.07 | 92 | 202 | 1.1 ± 4.07 | 2 | 6 | 3 h |
| MUA | 220 ± 4.18 | 10 | 22 | 10.0 ± 4.18 | 2 | 88 | 6 h |
| PEG | 430 ± 4.76 | 22 | 95 | 4.5 ± 4.76 | 7 | 71 | 3 h |
| PSSNA | 430 ± 4.33 | 23 | 99 | 4.3 ± 4.33 | 0 | 77 | 3 h |
| PVP | 430 ± 3.46 | 32 | 138 | 3.1 ± 3.46 | 2 | 66 | 3 h |
* The WST−1 column is the concentration at which the IC 30 was determined. The ICP-MS column shows where most of the GNP-ligands were situated. The normalized IC 30 is calculated based on cell internalization and WST-1 concentration. The ApoPercentage column is where the apoptotic induction time-point occurred.
Figure 4(a) Growth curve of the HepG2 cells after dosing them with the GNP-ligands using the IC 30 concentration determined by the impedance of the xCELLigence technology. (b) is the inverse graph of (a), where the cytotoxicity of the GNP-ligands has been determined. This data is based on an average of triplicate readings obtained for each concentration.
Figure 5Comet assay average tail intensity for each of the GNP-ligand IC 30 concentrations at the 0 h, 3 h, and 24 h time points.
Overall percentage of DNA damage induced by the GNP-ligands.
| Ligand | Time-Point at Which DNA Damage Was Determined # | |||
|---|---|---|---|---|
| 0 h | 3 h | 24 h | Welch | |
| BSA | 26 | 36 | 24 | 0.004 * |
| Citrate | 24 | 36 | 36 | 0.494 |
| GSH | 20 | 38 | 24 | 0.381 |
| MUA | 24 | 28 | 46 | 0.003 *** |
| PEG | 22 | 26 | 32 | 0.033 *** |
| PSSNA | 20 | 32 | 28 | 0.103 |
| PVP | 22 | 48 | 28 | 0.005 *,** |
| Positive control | 100 | 100 | 100 | 1 |
| Negative control | 12 | 12 | 12 | 1 |
# DNA damage is given as a percentage of the comet tail DNA. Approximately 50 comets were analyzed per treatment for each time point. * Significant difference between 0 and 3 h. ** Significant difference between 3 and 24 h. *** Significant difference between 0 and 24 h.
Comparison of GNP-ligand physical parameters and their effect on HepG2 cells.
| Ligand | DLS | Physio-Logical Charge | Cell Internalization | Fold Change in Cytotoxicity/Relative Cytotoxicity | Apoptosis | Cytotoxicity | DNA Damage | DNA Repair |
|---|---|---|---|---|---|---|---|---|
| BSA | 23.32 | Negative | 2 | 50.0 | Stepwise | 0 | Yes | Yes |
| Citrate | 17.4 | Negative | 17 | 5.9 | Stepwise | 4 | Yes | No |
| GSH | 17.33 | Negative | 92 | 1.1 | 3 h | 20 | Yes | Yes |
| MUA | 17.21 | Negative | 10 | 10.0 | 6 h | 18 | Yes | No |
| PEG | 18.86 | Neutral | 22 | 4.5 | 3 h | 22 | Yes | No |
| PSSNA | 17.26 | Negative | 23 | 4.3 | 3 h | 14 | Yes | Yes |
| PVP | 18.96 | Negative | 32 | 3.1 | 3 h | 17 | Yes | Yes |